Cargando…
Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
Kidney disease is one of the leading non-communicable diseases related to tremendous health and economic burden globally. Diabetes, hypertension, obesity and cardiovascular conditions are the major risk factors for kidney disease, followed by infections, toxicity and autoimmune causes. The peroxisom...
Autores principales: | Sharma, Vinesh, Patial, Vikram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634118/ https://www.ncbi.nlm.nih.gov/pubmed/36339586 http://dx.doi.org/10.3389/fphar.2022.991059 |
Ejemplares similares
-
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
por: Katoch, Swati, et al.
Publicado: (2022) -
The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases
por: Gao, Jianjun, et al.
Publicado: (2022) -
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014) -
Peroxisome Proliferator-Activated Receptor-Gamma Reduces ER Stress and Inflammation via Targeting NGBR Expression
por: Ma, Jialing, et al.
Publicado: (2022) -
Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats
por: Xia, Jingwen, et al.
Publicado: (2018)